Endometrial hyperplasia. Endometrial glandular hyperplasia
Conditions
Interventions
Intervention 1: Control group (40 patients) received 10 mg of medroxy progesterone from day 16 to 25 three-months. The patients were rechecked up after three and six months. Also Transvaginal sonograp
Treatment - Drugs
Control group (40 patients) received 10 mg of medroxy progesterone from day 16 to 25 three-months. The patients were rechecked up after three and six months. Also Transvaginal sonography and endometri
Interventional group (40 patients) was treated by letrozole through a dosage of one tablet (2.5mg) per day over three months. The patients were rechecked up after three and six months. Also Transvagin
Sponsors
Vice chancellor of research, Bushehr University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: women of reproductive age; non-pregnant; the diagnosis of endometrial hyperplasia as ultrasound and pathology. Exclusion criteria: side effects of letrozole; the prohibition of medicine prescription.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of letrozole on endometrial thickness. Timepoint: Three months and six months. Method of measurement: Transvaginal sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of irregular bleeding. Timepoint: Three months and six months. Method of measurement: History of the patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Elham Rahmani
Bushehr University of Medical Sciences
Outcome results
None listed